AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 320476 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion in addition to antibiotics
Number of subjects: 27
Study 320476 — intervention group
Group type: COMPARATOR
Intervention: Control group received appropriate antibiotic regimen alone
Number of subjects: 27
Study 6753860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate 50 mg/day
Number of subjects: 20
Study 6753860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg/day
Number of subjects: 20
Study 6753860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 554
Study 30554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injectable PrEP
Number of subjects: 554
Study 30554519 — intervention group
Group type: COMPARATOR
Intervention: On-demand PrEP
Number of subjects: 554
Study 30554519 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP across all hypothetical programs
Number of subjects: 554
Study 30554519 — intervention group
Group type: COMPARATOR
Intervention: Cost considerations
Number of subjects: 554
Study 30554519 — intervention group
Group type: COMPARATOR
Intervention: Interest in PrEP initiation
Number of subjects: 554
Study 30411751 — intervention group
Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 17
Study 30411751 — intervention group
Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 17
Study 26671188 — intervention group
Group type: EXPERIMENTAL
Intervention: DZQE
Number of subjects: 389
Study 26671188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formula
Number of subjects: 389
Study 26671188 — intervention group
Group type: COMPARATOR
Intervention: EZ
Number of subjects: 389
Study 25152283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral transversus abdominis plane block with 0.25% ropivacaine 60 ml (group A)
Number of subjects: 40
Study 22246200 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (50 mg/ml)
Number of subjects: 80
Study 22246200 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (0.01%)
Number of subjects: 80
Study 20107141 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (Sprinkles)
Number of subjects: 268
Study 20107141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 268
Study 20107141 — intervention group
Group type: COMPARATOR
Intervention: Nutrivida
Number of subjects: 268
Study 18206039 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.4 mg qd at 10PM for 3 days, n = 72)
Number of subjects: 142
Study 18206039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 142
Study 15234399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment with clopidogrel for three days
Number of subjects: 203
Study 15234399 — intervention group
Group type: COMPARATOR
Intervention: Standard post-procedural treatment (Control)
Number of subjects: 203
Study 11383794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 300 mg bolus followed by 1.5 mg.kg(‐1).h(‐1) continuous infusion for 2 days
Number of subjects: 30
Study 11383794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study 11383794 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 9493673 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 22
Study 9493673 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 22
Study 8364942 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ketorolac tromethamine
Number of subjects: 207
Study 8364942 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of hydrocodone plus 1000 mg of acetaminophen
Number of subjects: 207
Study 8364942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 3640135 — intervention group
Group type: EXPERIMENTAL
Intervention: Future Fit cardiovascular health education and fitness program
Number of subjects: 55
Study 3640135 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 55
Study 28746076 — intervention group
Group type: EXPERIMENTAL
Intervention: Neublastin 50 μg/kg
Number of subjects: 176
Study 28746076 — intervention group
Group type: EXPERIMENTAL
Intervention: Neublastin 1200 μg/kg
Number of subjects: 176
Study 28746076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 28746076 — intervention group
Group type: EXPERIMENTAL
Intervention: All neublastin doses
Number of subjects: 176
Study 26135333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray during follicular phase (F)
Number of subjects: 116
Study 26135333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray during luteal phase (L)
Number of subjects: 116
Study 25713924 — intervention group
Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (VCE) using the PillCam SB capsule endoscopy system
Number of subjects: 8
Study 25713924 — intervention group
Group type: COMPARATOR
Intervention: 13C breath test using BreathID system
Number of subjects: 8
Study 22811030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate supplementation (10 mg·kg of body mass)
Number of subjects: 13
Study 22811030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate supplementation
Number of subjects: 13
Study 22811030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19649341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90
Study 19649341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90
Study 19649341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17503683 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider responses to computer alerts regarding guideline recommendations for antihypertensive treatment.
Number of subjects: 1017
Study 17503683 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertia of practice among providers.
Number of subjects: 1017
Study 15709563 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 52
Study 15709563 — intervention group
Group type: COMPARATOR
Intervention: Didactic Lecture
Number of subjects: 52
Study 15709563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 15709563 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL
Number of subjects: 52
Study 11349696 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall (ADL)
Number of subjects: 137
Study 11349696 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 137
Study 11349696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 11349696 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/dose
Number of subjects: 137
Study 11349696 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/dose
Number of subjects: 137
Study 11349696 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/dose
Number of subjects: 137
Study 9484545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride during fasting
Number of subjects: 10
Study 9484545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride followed 30 minutes later by ingestion of 300 mL of milk
Number of subjects: 10
Study 9484545 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet during fasting
Number of subjects: 10
Study 9484545 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet followed 30 minutes later by ingestion of 300 mL of milk
Number of subjects: 10
Study 7869731 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg plus Hydrochlorothiazide 25 mg (BN + HCT)
Number of subjects: 18
Study 7869731 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus Hydrochlorothiazide 25 mg (CP + HCT)
Number of subjects: 18
Study 7869731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3285831 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 18
Study 3285831 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 18
Study 31135090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (placebo-controlled trial)
Number of subjects: 206
Study 31135090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 206
Study 31135090 — intervention group
Group type: EXPERIMENTAL
Intervention: Education provided during recruitment
Number of subjects: 206
Study 31135090 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's current poor state of health
Number of subjects: 206
Study 31135090 — intervention group
Group type: EXPERIMENTAL
Intervention: Possibility of improvement in child's health
Number of subjects: 206
Study 30963591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus SP1
Number of subjects: 36
Study 30963591 — intervention group
Group type: COMPARATOR
Intervention: Control group (milk without probiotic)
Number of subjects: 36
Study 28093194 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency and intensity neuromuscular electrical stimulation (50Hz, 72.90mA, 3 times per week for 1 hour, 12 sessions)
Number of subjects: 51
Study 28093194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency and intensity neuromuscular electrical stimulation (5Hz, 13.85mA, 3 times per week for 1 hour, 12 sessions)
Number of subjects: 51
Study 28093194 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency and intensity neuromuscular electrical stimulation
Number of subjects: 51
Study 28093194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency and intensity neuromuscular electrical stimulation
Number of subjects: 51
Study 28093194 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study 26459650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 81
Study 26459650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 22882673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol therapy (50 to 200 mg/day)
Number of subjects: 100
Study 22882673 — intervention group
Group type: COMPARATOR
Intervention: Rescue analgesia (topical cream with 3.33% doxepin and 0.05% capsaicin)
Number of subjects: 100
Study 21126595 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted CD34(+) cell dose levels: 2-4 × 10(6) cells/kg, 4-6 × 10(6) cells/kg, >6 × 10(6) cells/kg
Number of subjects: 438
Study 19692265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 40
Study 19692265 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 40
Study 17668526 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (CLIN/RA gel)
Number of subjects: 4500
Study 17668526 — intervention group
Group type: COMPARATOR
Intervention: Individual components (clindamycin phosphate 1.2% or tretinoin 0.025%)
Number of subjects: 4500
Study 15479494 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 100 mg/m2 plus estramustine 280 mg orally 3 times a day
Number of subjects: 163
Study 15479494 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 100 mg/m2 alone
Number of subjects: 163
Study 12964350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocellular foam (Allevyn, Smith and Nephew)
Number of subjects: 20
Study 12964350 — intervention group
Group type: COMPARATOR
Intervention: Calcium alginate (Kaltostat, ConvaTec)
Number of subjects: 20
Study 9825177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5.0 mg
Number of subjects: 14
Study 9825177 — intervention group
Group type: EXPERIMENTAL
Intervention: d-nebivolol 2.5 mg
Number of subjects: 14
Study 9825177 — intervention group
Group type: COMPARATOR
Intervention: l-nebivolol 2.5 mg
Number of subjects: 14
Study 9825177 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 14
Study 9825177 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic nebivolol (2.5, 5.0, and 10.0 mg)
Number of subjects: 14
Study 9825177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 14
Study 8074059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms/kg) combined with caffeine (5 mg/kg) during activity
Number of subjects: 20
Study 8074059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms/kg) during activity
Number of subjects: 20
Study 8074059 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg) during activity
Number of subjects: 20
Study 8074059 — intervention group
Group type: COMPARATOR
Intervention: Placebo during activity
Number of subjects: 20
Study 2510845 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg elemental zinc daily)
Number of subjects: 494
Study 2510845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsule identical in appearance and taste with inert substances)
Number of subjects: 494
Study 31782961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 123
Study 31782961 — intervention group
Group type: COMPARATOR
Intervention: Sleepiness
Number of subjects: 123
Study 31051248 — intervention group
Group type: COMPARATOR
Intervention: SMS reminder
Number of subjects: 709
Study 31051248 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone reminder
Number of subjects: 709
Study 29231502 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular sticking therapy with semen vaccariae, applied every three days for 2 weeks, combined with western medication.
Number of subjects: 90
Study 29231502 — intervention group
Group type: COMPARATOR
Intervention: Auricular pseudo-press therapy, applied every three days for 2 weeks, combined with western medication.
Number of subjects: 90
Study 25788172 — intervention group
Group type: EXPERIMENTAL
Intervention: Portland cement (PC)
Number of subjects: 30
Study 25788172 — intervention group
Group type: EXPERIMENTAL
Intervention: PC with iodoform (PC + CHI(3))
Number of subjects: 30
Study 25788172 — intervention group
Group type: EXPERIMENTAL
Intervention: PC with zirconium oxide (PC + ZrO(2))
Number of subjects: 30
Study 23524173 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 94
Study 23524173 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 94
Study 21565921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free inhalator group (PAIPO)
Number of subjects: 120
Study 21565921 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 120
Study 19360477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Tactile Display (DTD)
Number of subjects: 24
Study 19360477 — intervention group
Group type: COMPARATOR
Intervention: Belt Tactile Display (TB)
Number of subjects: 24
Study 16720537 — intervention group
Group type: EXPERIMENTAL
Intervention: General and tailored CRC risk factor feedback (absolute risk group)
Number of subjects: 160
Study 16720537 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute CRC risk factor feedback plus CRC feedback as to how their total number of risk factors compared with that of others (absolute plus comparative risk group)
Number of subjects: 160
Study 16720537 — intervention group
Group type: COMPARATOR
Intervention: General CRC risk factors (control)
Number of subjects: 160
Study 16720537 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants informed they were at lower comparative risk
Number of subjects: 160
Study 15228966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotrol nicotine inhaler (OTC)
Number of subjects: 520
Study 15228966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotrol nicotine inhaler (HCP)
Number of subjects: 520
Study 11325322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant medication (amitriptyline hydrochloride, up to 100 mg/d, or nortriptyline hydrochloride, up to 75 mg/d)
Number of subjects: 203
Study 11325322 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management therapy (3 sessions and 2 telephone contacts) plus placebo
Number of subjects: 203
Study 11325322 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management therapy plus antidepressant medication
Number of subjects: 203
Study 11325322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 9513669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 40 mg
Number of subjects: 0
Study 9513669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1884268 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative and post-ECC transfusion of blood removed after induction of anaesthesia (Group I)
Number of subjects: 74
Study 1884268 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative transfusion of extravasated thoracic blood (Group II)
Number of subjects: 74
Study 1884268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of peroperative and postoperative transfusion (Group III)
Number of subjects: 74
Study 1884268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 6411615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat tolerance test
Number of subjects: 10
Study 6411615 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused fat during 24 hours
Number of subjects: 10
Study 6411615 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure and nitrogen balance
Number of subjects: 10
Study 6411615 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate oxidation
Number of subjects: 10
Study 6411615 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with fat dosage of 2.5 g/kg X d‐1
Number of subjects: 10
Study 6411615 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 10
Study 31818053 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasonography (MSUS)
Number of subjects: 0
Study 31818053 — intervention group
Group type: COMPARATOR
Intervention: Sports medicine physician (SMP)
Number of subjects: 0
Study 31386203 — intervention group
Group type: EXPERIMENTAL
Intervention: on‐BEAM intervention (personalized normative feedback and motivational interviewing techniques)
Number of subjects: 1496
Study 31386203 — intervention group
Group type: EXPERIMENTAL
Intervention: on‐BEAM intervention
Number of subjects: 1496
Study 31386203 — intervention group
Group type: COMPARATOR
Intervention: Control group (assessment and results without normative feedback)
Number of subjects: 1496
Study 28323797 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vancomycin powder (up to a maximum dose of 1000 mg, placed immediately before wound closure)
Number of subjects: 500
Study 28323797 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 500
Study 27475691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System (FTS)
Number of subjects: 17
Study 27475691 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo patch and analgesic)
Number of subjects: 17
Study 24011845 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (managed pharmacologically according to the protocol)
Number of subjects: 201
Study 24011845 — intervention group
Group type: COMPARATOR
Intervention: Control group (managed according to ICU routine)
Number of subjects: 201
Study 21037490 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid, 2 g/d)
Number of subjects: 20
Study 20110013 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of rebamipide 100 mg
Number of subjects: 30
Study 20110013 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of rebamipide 100 mg
Number of subjects: 30
Study 20110013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study 17203281 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose
Number of subjects: 31
Study 17203281 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose
Number of subjects: 31
Study 17203281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 31
Study 15271730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 20
Study 15271730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 20
Study 15271730 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected side
Number of subjects: 20
Study 15271730 — intervention group
Group type: COMPARATOR
Intervention: Control side
Number of subjects: 20
Study 15271730 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in VNRS score
Number of subjects: 20
Study 11234938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands of diabetic patients
Number of subjects: 100
Study 11234938 — intervention group
Group type: EXPERIMENTAL
Intervention: Feet of diabetic patients
Number of subjects: 100
Study 11234938 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetics
Number of subjects: 100
Study 11234938 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetics
Number of subjects: 100
Study 10225575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (100 mg bd for 3 days)
Number of subjects: 713
Study 10225575 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (160/800 mg bd for 7 days)
Number of subjects: 713
Study 10225575 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin (100 mg bd for 7 days)
Number of subjects: 713
Study 10225575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 713
Study 10225575 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 713
Study 8059818 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene (treatment group, n = 12)
Number of subjects: 25
Study 8059818 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraception (control group, n = 13)
Number of subjects: 25
Study 2741619 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose-saline infusion
Number of subjects: 2
Study 2741619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour glucose infusion
Number of subjects: 2